Study supports safety of perfluorocarbon ventilation:
This article was originally published in Clinica
Executive Summary
Partial liquid ventilation (PLV) is safe for acute respiratory failure patients. Overall survival was 50% in a non-controlled, Phase I experimental study of perfluorocarbon ventilation at the University of Michigan surgical intensive care unit. Only 10-20% of such patients normally survive rising to 50-60% if they can be supported by extracorporeal life support (ECLS). Writing in JAMA (February 7th), Dr Ronald Hirschl says ECLS patients were chosen in case PLV compromised native lung gas exchange. A Phase I/II study will investigate less seriously injured patients who are not receiving ECLS.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.